tiprankstipranks
Advertisement
Advertisement

LEGN Stock Latest News

Legend Biotech Reports Preliminary Q1 2026 CARVYKTI Sales of About $597 Million
Company AnnouncementsLegend Biotech Reports Preliminary Q1 2026 CARVYKTI Sales of About $597 Million
22d ago
6K
LEGN
Legend Biotech Earnings Call Highlights CARVYKTI Momentum
PremiumCompany Announcements
Legend Biotech Earnings Call Highlights CARVYKTI Momentum
1M ago
LEGN
Reiterating Buy on Legend Biotech: CARVYKTI’s Entrenched Efficacy and Operational Lead Underappreciated vs. Emerging Competition
PremiumRatings
Reiterating Buy on Legend Biotech: CARVYKTI’s Entrenched Efficacy and Operational Lead Underappreciated vs. Emerging Competition
2M ago
LEGN
Legend Biotech price target lowered to $49 from $50 at Morgan Stanley
PremiumThe Fly
Legend Biotech price target lowered to $49 from $50 at Morgan Stanley
2M ago
LEGN
Legend Biotech price target lowered to $62 from $66 at RBC Capital
PremiumThe Fly
Legend Biotech price target lowered to $62 from $66 at RBC Capital
2M ago
LEGN
Legend Biotech Posts 2025 CARVYKTI Profitability and Tops 10,000 Patients Treated
PremiumCompany AnnouncementsLegend Biotech Posts 2025 CARVYKTI Profitability and Tops 10,000 Patients Treated
2M ago
6K
LEGN
Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year
Premium
The Fly
Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year
2M ago
LEGN
Legend Biotech sees cash runway beyond 2026
Premium
The Fly
Legend Biotech sees cash runway beyond 2026
2M ago
LEGN
Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank
PremiumThe Fly
Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank
2M ago
LEGN
LEGN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
LEGN Upcoming Earnings Report: What to Expect?
2M ago
LEGN
Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target
PremiumRatings
Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target
2M ago
LEGN
Legend Biotech rises 16.6%
PremiumThe Fly
Legend Biotech rises 16.6%
2M ago
LEGN
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
PremiumThe FlyLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
3M ago
LEGN
Legend Biotech Names Veteran Finance Executive Gareth Kung to Board and Audit Chair Role
Premium
Company Announcements
Legend Biotech Names Veteran Finance Executive Gareth Kung to Board and Audit Chair Role
3M ago
6K
LEGN
Legend Biotech price target lowered to $80 from $90 at Barclays
Premium
The Fly
Legend Biotech price target lowered to $80 from $90 at Barclays
3M ago
LEGN
Legend Biotech Reshapes Board, Appoints GenScript Chairman Robin Meng as Director
PremiumCompany Announcements
Legend Biotech Reshapes Board, Appoints GenScript Chairman Robin Meng as Director
3M ago
6K
LEGN
Legend Biotech: Undervalued CARVYKTI Leader Offering a Compelling Buy Opportunity Despite Transient Setback
PremiumRatings
Legend Biotech: Undervalued CARVYKTI Leader Offering a Compelling Buy Opportunity Despite Transient Setback
3M ago
LEGN
Legend Biotech price target lowered to $50 from $60 at H.C. Wainwright
PremiumThe Fly
Legend Biotech price target lowered to $50 from $60 at H.C. Wainwright
3M ago
LEGN
Legend Biotech downgraded to Hold from Buy at TD Cowen
PremiumThe Fly
Legend Biotech downgraded to Hold from Buy at TD Cowen
3M ago
LEGN
Legend Biotech falls -12.7%
PremiumThe FlyLegend Biotech falls -12.7%
3M ago
LEGN
Legend Biotech falls -10.5%
Premium
The Fly
Legend Biotech falls -10.5%
3M ago
LEGN
Legend Biotech Announces Preliminary Q4 2025 CARVYKTI Sales of Approximately $555 Million
Premium
Company Announcements
Legend Biotech Announces Preliminary Q4 2025 CARVYKTI Sales of Approximately $555 Million
3M ago
6K
LEGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >